Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Mainz – page 42

604 clinical trials in Mainz, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Mainz at a glance
604
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

604 trials in Mainz

Open in trial search

Non-small cell lung cancer

Not recruiting

Study of Tiragolumab, Atezolizumab, and Pembrolizumab for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Chronic lymphocytic leukaemia+2

Not recruiting

Study on the Safety and Effectiveness of Mosunetuzumab and Atezolizumab for Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Genentech Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Amlitelimab for Patients Aged 12 and Older with Moderate-to-Severe Atopic Dermatitis Using Topical Corticosteroids

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Mantle cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Pirtobrutinib vs. Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Loxo Oncology Inc.

Pulmonary hypertension

Not recruiting

Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Pulmonary embolism

Not recruiting

Study on Reduced Dose of Alteplase for Patients with Intermediate-High-Risk Acute Pulmonary Embolism

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic lupus erythematosus

Not recruiting

Study on Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Pulmonary hypertension

Not recruiting

Study on the Long-term Safety and Efficacy of Ralinepag for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Fabry's disease

Not recruiting

Study of venglustat tablets to reduce neuropathic and abdominal pain in patients aged 16 and older with Fabry disease who are untreated or haven't received treatment for 6 months

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Venglustat
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Melanoma Treatment: Comparing Encorafenib and Binimetinib with Ipilimumab and Nivolumab for Patients with BRAF V600 Mutation

Not recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Mainz

What the registry says about research in the country

01 Infectious Disease Prevention

Groundbreaking trials focusing on viral infections including studies of vaccines against Respiratory Syncytial Virus, Herpes Zoster, and Cytomegalovirus. Research aims to evaluate vaccine efficacy and immune response in different age groups.

  • RSV and hMPV Prevention
  • Herpes Zoster Protection
  • CMV Vaccine Development

Special attention is given to protecting vulnerable populations, including older adults and those at increased risk.

02 Oncology Research

Innovative clinical trials targeting various forms of cancer, including studies on breast cancer, pancreatic cancer, and multiple myeloma. Research focuses on novel therapeutic approaches and combination treatments.

  • Advanced Breast Cancer Therapy
  • Gastric Cancer Treatment
  • Lymphoma Management

Emphasis on personalized medicine approaches and targeted therapies for better patient outcomes.

03 Chronic Disease Management

Comprehensive studies addressing respiratory conditions, autoimmune disorders, and metabolic diseases. Research includes treatments for asthma, multiple sclerosis, and obesity.

  • Pulmonary Hypertension
  • Chronic Kidney Disease
  • Autoimmune Conditions

Focus on developing long-term treatment solutions and improving quality of life for patients.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.